Table 4 Multivariate analysis for cardiovascular-related mortality.

From: Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3–5

Model

Variable

p valuea

SHR

CI 95%

Crude model

OPG

< 0.001

1.10

1.05–1.15

Model 1

OPG

< 0.001

1.10

1.04–1.15

Age

0.855

1.00

0.97–1.03

Sex (male)

0.879

0.94

0.44–2.02

Model 2

OPG

< 0.001

1.10

1.04–1.16

Age

0.929

1.00

0.97–1.03

Sex (male)

0.833

0.92

0.43–1.99

Diabetes

0.783

1.12

0.50–2.53

CVD

0.426

1.43

0.60–3.42

Model 3

OPG

0.001

1.10

1.04–1.16

Age

0.757

1.00

0.96–1.03

Sex (male)

0.904

1.05

0.48–2.30

Diabetes

0.687

1.18

0.52–2.68

CVD

0.340

1.53

0.64–3.66

hsCRP

0.885

1.00

0.96–1.04

Model 4

OPG

0.074

1.06

0.99–1.13

Age

0.668

1.01

0.97–1.04

Sex (male)

0.668

1.19

0.54–2.64

Diabetes

0.616

1.24

0.54–2.83

CVD

0.588

1.28

0.52–3.15

hsCRP

0.869

1.00

0.96–1.04

CKD stage

3 (ref)*

   

4

0.664

1.72

0.15–19.6

5

0.105

5.34

0.71–40.4

  1. Fine and Gray model for mortality (cardiovascular causes) considering transplant and other cause of mortality as competing risk.
  2. aStage 3 used as a reference for the analysis
  3. OPG, osteoprotegerin; CVD, cardiovascular disease; hsCRP, high-sensitivity C-reactive protein; CKD, chronic kidney disease; SHR: subdistribution hazard ratio.
Back to article page